AbbVie’s $2.7B IPR&D charge hits Q3 and full-year EPS guidance; Street recalibrates expectations. Reuters reports ABBV now sees FY25 adjusted EPS at $10.38–$10.58 (prior $11.88–$12.08) and prelim Q3 EPS at $1.74–$1.78, both below consensus. The charge stems from acquired in-process R&D tied to deals/licensing. This signals continued external pipeline spending even as Humira wanes and newer drugs scale. SummaryAbbVie is prioritizing pipeline building via deals, taking a large non-cash IPR&D expense in Q3 that lowers near-term EPS but implies sustained outsourcing and partnered development activity across immunology, oncology, and neuroscience. WinnersCategory: Contract Research Organizations (CROs)Reason: Large pharma IPR&D and partnered assets typically rely on external trial execution; elevated deal flow and program hand-offs tend to lift CRO backlog and visibility when a sponsor leans into partnerships.Names: $IQV (IQVIA), $CRL (Charles River Laboratories)Category: Drug-development Tools and Bioprocess SuppliersReason: More partnered and acquired programs moving into clinic and scale-up can drive demand for analytics, instruments, and bioprocess solutions used across trials and manufacturing.Names: $TMO (Thermo Fisher Scientific), $DHR (Danaher)Category: US-listed Biotech with Partnerable AssetsReason: A headline IPR&D charge highlights active BD/licensing; mid/small-cap names with late-stage or best-in-class assets in ABBV focus areas often see stronger inbound interest, term sheets, or comps.Names: $IONS (Ionis Pharmaceuticals), $VKTX (Viking Therapeutics)LosersCategory: AbbVie and Guidance-Sensitive Pharma HoldingsReason: The immediate impact is lower reported EPS and narrower FY guide; guidance cuts often pressure valuation for income/growth-at-a-reasonable-price holders.Names: $ABBV (AbbVie), $BMY (Bristol Myers Squibb) as a peer exposed to guidance-watching investors and deal-related expense optics. Category: Dividend-Tilted Mega-Cap Pharma Sentiment Read-ThroughReason: When a top-10 pharma prints a big IPR&D hit and trims guidance, investors may extrapolate sector-wide EPS volatility for other acquirers doing external pipeline deals.Names: $PFE (Pfizer), $MRK (Merck)Category: Near-Term Competitors Facing a Re-tooled ABBV PipelineReason: Aggressive BD spend implies ABBV will keep fortifying immunology/oncology franchises; competitors in adjacent indications can face tougher trial and commercial matchups over time.Names: $AMGN (Amgen), $LLY (Eli Lilly)Trading angles and risk managementShort-term: Consider whether ABBV’s gap reflects one-off accounting vs. cash-flow durability; watch Q3 print and color on deal pipeline. Relative trades: CRO/tools strength on backlog commentary vs. large-cap pharma multiple drift if investors price more IPR&D noise sector-wide.Catalyst watch: Any follow-on 8-K or call detailing which assets drove the charge; updates on Skyrizi/Rinvoq trajectories and BD cadence. #StockMarket #Trading #Investing #DayTrading #SwingTrading #Biotech #Pharma #Earnings #HealthcareStocks #MergersAndAcquisitions #RAndD

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.